Abstracts Archive - Page 224 of 2607 - ACR Meeting Abstracts

Abstract Number: PP14 • ACR Convergence 2024
Support Groups and Chronic Illness: Finding Social Support Among Peers
Alexandra Blumhorst¹ and Estela Mata-Carcamo², ¹Looms for Lupus, Silver Spring, MD, ²Looms for Lupus, Irwindale, CA
Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
Abstract Number: 2651 • ACR Convergence 2024
Vasculitis Associated with VEXAS Syndrome
Megan Sullivan¹, Kambiz Kalantari², Carolyn Mead-Harvey³, Yael Kusne⁴, Mrinal Patnaik², Abhishek Mangaonkar², Ronald Go², Daniel Montes², Kaaren Reichard², Horatiu Olteanu², Melanie Bois², Alexander Hines², Julio Sartori-Valinotti⁵, Kenneth Warrington² and Matthew Koster², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Scottsdale, AZ, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic, Rohester, MN
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description…
Abstract Number: 2680 • ACR Convergence 2024
Thrombocytopenia in Patients with Systemic Lupus ErythematosusReal-World Data Based on a Nationwide Database, RISE
Omer Pamuk¹, Jessica Fitzpatrick², Jing Li³, Gabriela Schmajuk⁴ and Marina Magrey⁵, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a very heterogeneous presentation. Thrombocytopenia (TP) is an infrequent presentation in patients with SLE…
Abstract Number: PP05 • ACR Convergence 2024
Reunion with Forgotten Relationships and Memories
Noriko Okochi¹, Eiji Oishi², Kaoru Mitsuyama³, Emi Sorimachi³, Shiho Bando⁴, Yuka Hirama⁵, Nobuyuki Yajima⁶ and Masaaki Mori⁷, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan, ³Institute of Neuropsychiatry, Tokyo, Tokyo, Japan, ⁴Ota-ku Children and Families Support Center, Ota-ku, Tokyo, Japan, ⁵Asada Ladies Clinic, Shinagawa, Japan, Tokyo, Japan, ⁶Showa-Universtiy of Medicine, Tokyo, Japan, ⁷Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Paediatric rheumatic diseases are complex experiences for children. For children whose language skills are still undeveloped, it is difficult for them to put their…
Abstract Number: PP13 • ACR Convergence 2024
Bridging the Gap from Pediatric to Adult Rheumatology Care
Natasha Trehan, University of Ottawa, Take a Pain Check Foundation, Markham, ON, Canada
Background/Purpose: When I was 13, life took an unexpected turn with a diagnosis of Juvenile Idiopathic Arthritis (JIA). Overnight, my world transformed into a cycle…
Abstract Number: PP08 • ACR Convergence 2024
Whispers of Resilience: Navigating Life with Rheumatism
Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
Abstract Number: 2492 • ACR Convergence 2024
ANCA Associated Tracheobronchial Disease
Megan Sullivan¹, Maximiliano Diaz Menindez², Ronald Butendieck³, hassan baig⁴, Anushka Irani⁵, Benjamin Wang³, Florentina Berianu⁵, Carolyn Mead-Harvey⁶, Andy Abril⁵ and Vikas Majithia⁴, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic, Ponte Vedra Beach, FL, ⁶Mayo Clinic, Scottsdale, AZ
Background/Purpose: Tracheobronchial disease is a common manifestation of ANCA associated vasculitis (AAV). However, outcomes data is commonly unreported in prospective studies. We performed a retrospective…
Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
James Bistolarides¹, Vidya Sivaraman², Else Bosman³, Linda Wagner-Weiner⁴, Kimberly Morishita⁵, James Nocton¹, Melodee Liegl¹, Amy Pan¹ and David Cabral⁶, and PedVas Investigators Network, ¹Medical College of Wisconsin, Milwaukee, WI, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³UBC, Vancouver, BC, Canada, ⁴University of Chicago, Chicago, IL, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
Abstract Number: 2503 • ACR Convergence 2024
Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben
Frank S Czerwiec¹, Irina Bancos², Paul M Stewart³, Ketan Desai¹ and David A Katz¹, ¹Sparrow Pharmaceuticals, Portland, OR, ²Mayo Clinic, Rochester, MN, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Approximately 1% of the population rely on chronic glucocorticoid (GC) prescription to control autoimmune and inflammatory conditions. Risk of GC induced adrenal insufficiency (GC-AI)…
Abstract Number: 2687 • ACR Convergence 2024
Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts
Michael Macklin¹, Iazsmin Bauer Ventura¹ and Dinesh Khanna², ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
Abstract Number: 2631 • ACR Convergence 2024
Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study
Pierre Loiseau¹, Aurélie Mailhac², Pierre Duhaut¹, Henrik Toft Sørensen² and Reimar W Thomsen², ¹Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France, ²Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: There is evidence of an increased risk of cardiovascular disease in several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In primary…
Abstract Number: 2642 • ACR Convergence 2024
Identifying Systemic Sclerosis Molecular Subtypes by Their Cellular Signature – Deconvoluting the Puzzle
Erik Feldman¹, Neta Milman¹, Shai S. Shen-Orr¹ and Doron Rimar², ¹1. Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel
Background/Purpose: RNA gene expression allows to identify differentially expressed genes (DEG) in Systemic sclerosis (SSc) patients compared to healthy controls. Using unsupervised machine learning Milano…
Abstract Number: 2536 • ACR Convergence 2024
Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Adam Cantor¹, Alba Boix-Amoros³, Jose Scher⁴ and Jose Clemente¹, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
Abstract Number: 2661 • ACR Convergence 2024
Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)
Fredeswinda Romero-Bueno¹, María Carmen Vegas-Sánchez², lydia Abasolo Alcazar³, Mª Jesus Rodriguez Nieto², Cristina Vadillo-Font⁴, M Asuncion Nieto⁵, Laura Cebrián⁶, Belén López-Muñiz⁶, Jesus Loarce Martos⁷, Juan Rigual⁸, hildegarda Godoy Tundidor⁹, Rosalía Laporta¹⁰, Irene Llorente-Cubas¹¹, Gema Bonilla¹², Luis Gomez Carrera¹³, Rosario García-Vicuña¹⁴, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁵ and Olga Sánchez-Pernaute¹⁶, and the NEREA Study group for Autoimmune ILD, ¹Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³IdISSC. HCSC, Madrid, Spain, ⁴Hospital Clinico S Carlos, Madrid, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ¹⁰Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹¹Hospital Universitario de La Princesa, Madrid, Spain, ¹²H. Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹⁵Hospital Universitario La Princesa, Madrid, Spain, ¹⁶Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is a mucin-1 glycoprotein produced by type 2 alveolar epithelial cells , which increase at peripheral blood show a…
Abstract Number: 2544 • ACR Convergence 2024
Spatial Transcriptomics Suggests Synovial Macrophage Niches Are Sexually Dimorphic in a Mouse Inflammatory Arthritis Model
Richard Bell¹, Ruoxi Yuan², Mary Huang², Ewurama Cann², Chao Yang², Franck Barrat¹ and Lionel Ivashkiv¹, ¹Hospital for Special Surgery, New York, NY, ²HSS, New York, NY
Background/Purpose: Monocytes and Macrophages (MФ) play a key pathogenic role in Rheumatoid Arthritis (RA), a disease that exhibits female sex bias. Recent work using scRNAseq…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].